Norrin Protects Vision in Diabetic Rats

University of Michigan researchers found the protein norrin prevented vision loss in diabetic rats in a study published in the journal Diabetes.

Updated on Nov. 3, 2026 in Diabetes

Laboratory bench with clear glass vials of pale amber liquid and a retinal-imaging microscope in soft focus under soft daylight from a window. — University of Michigan researchers reported that injecting the protein norrin prevented vision loss and retinal cell death in diabetic rats, according to a study published in Diabetes. AI Illustration. Upload story photo >

Researchers at the University of Michigan reported that injecting norrin prevented vision loss and retinal cell death in diabetic rats. The study, published in Diabetes, suggests a possible new approach to diabetic retinopathy.

Why it matters

Current treatments target vascular endothelial growth factor, but anti-VEGF agents require several injections and fail to fully manage half of treated patients. A norrin-based approach could offer an alternative for people with diabetes in the Ann Arbor area and beyond.

The study is an animal trial in which norrin injection prevented vision loss in diabetic rats, while current anti-VEGF therapies fail to fully manage half of treated patients. Whether these results will translate to human patients remains unknown.

The players

University of Michigan

A public research university in Ann Arbor, Michigan, whose researchers conducted the study on norrin and diabetic retinopathy.

Kellogg Eye Center

The eye care and research center at the University of Michigan that is affiliated with the researchers who conducted the study.

The details

Researchers injected norrin into diabetic rats at early and late stages of diabetes and found it prevented retinal cell death and inflammation. Starting treatment after vision loss had already begun still prevented further decline, and the team identified several genes affected by norrin treatment.

The study was published in the journal Diabetes on November 3, 2026.
The Antonetti lab has worked on norrin effects for several years.

Health Landscape

Anti-VEGF drugs have been the standard for diabetic retinopathy, but they require repeated injections and do not fully control the disease for half of patients. The norrin research points to a different pathway that could complement or eventually reduce reliance on those therapies.

This research is at the animal stage, so no change to treatment is available yet for people with diabetic retinopathy. Anyone with diabetes should continue regular eye exams and current care plans while further studies are conducted.

The takeaway

Regular dilated eye exams remain the most reliable way for people with diabetes to catch retinopathy early. Ask your eye care provider about monitoring options as new research develops.